ALMR ALMR
Company Profile ↓Company Overview
ALMR (ALMR) is a publicly traded company listed on with a market capitalization of $1.89B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 18.8%, reflecting efficient use of shareholder capital.
Revenue has grown at a 195.2% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $74.21M (+195.2% YoY); net profit $-29.82M.
- Trailing 12 Months Year-on-year growth — revenue +195.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 195.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 195.17% |
| 1 Year: | 195.17% |
Stock Price Performance
| 1 Year: | +28.86% |
| 6 Months: | - |
| 3 Months: | +18.62% |
| 1 Month: | +12.37% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)63.92 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 195.2% over 5 years.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 13.09M | 26.04M |
| Cost of Revenue | 6.70M | 11.58M |
| Gross Profit | 6.39M | 14.46M |
| Operating Expenses | 14.94M | 26.80M |
| Operating Income | -8.55M | -12.35M |
| EBITDA | -6.72M | -19.47M |
| Interest Expense | 46.00K | 223.00K |
| Pretax Income | -7.66M | -20.86M |
| Tax Provision | 0 | 464.00K |
| Net Income | -7.66M | -21.32M |
| Diluted EPS | -0.12 | -0.32 |
| R&D Expense | 8.30M | 13.02M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 25.14M | 74.21M |
| Cost of Revenue | 16.54M | 32.51M |
| Gross Profit | 8.61M | 41.70M |
| Operating Expenses | 58.17M | 73.04M |
| Operating Income | -49.57M | -31.33M |
| EBITDA | -41.79M | -24.89M |
| Interest Expense | 2.08M | 401.00K |
| Pretax Income | -47.06M | -29.15M |
| Tax Provision | 13.00K | 665.00K |
| Net Income | -47.07M | -29.82M |
| Diluted EPS | -0.71 | -0.45 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 149.51M | 139.99M |
| Current Assets | 106.70M | 94.70M |
| Cash & Equivalents | 26.77M | 30.00M |
| Inventory | 14.41M | 38.48M |
| Receivables | 6.65M | 12.75M |
| Total Liabilities | 282.92M | 298.95M |
| Current Liabilities | 16.59M | 23.73M |
| Long Term Debt | - | 9.81M |
| Total Debt | 33.10M | 41.47M |
| Total Equity | -133.41M | -158.95M |
| Shares Outstanding | 66.52M | 66.52M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -55.21M | -53.61M |
| Investing Cash Flow | -53.93M | 46.18M |
| Financing Cash Flow | 113.42M | 10.84M |
| Capital Expenditure | -3.39M | -6.38M |
| Free Cash Flow | -58.60M | -59.99M |
| Net Change in Cash | 4.27M | 3.40M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | 34.2% | 56.2% |
| Operating Margin % | -197.2% | -42.2% |
| Net Margin % | -187.2% | -40.2% |
| ROE % | 35.3% | 18.8% |
| ROCE % | -37.3% | -27.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALMR
Evaluating Alamar Biosciences (ALMR) Valuation As Shares Show Modest Year To Date Gains - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNS3VYU05uajNFZkNWa25vTURGREJfYWprazRKQ1lEcm1oRjhVTXdqTTcwZ1dhTkQ5YndoVFpka1J2QzVnTTl5UllsTVAwd29ubE9lOEtQWXpnQmlKYjdvZkRaQ0Jya0R2VHZ1ZGNjb19TWFdWWVdEekZCbVA5LW1VUS1DYU1QS1dJQTg2M2…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBVSURpUWZBWENfcXdhaHVsMDBjaTk4bTFzQ3g0Zm5wVmpmWTV3ZkZKU19Ja1QzWUR4ZFFsalFVb1VRN0VOc0FiRGY5d0l5QWNC?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
One sample, about 340 immune proteins: Alamar’s new panel - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQQ3R5Slg3NWVMbEZGZGNaN2hKZlJFX0lwRk9nbDBqem05eTNCaW5sNXozNThfbWhZRi1UUENRbE96Y0xHWi1DdWlfWjFjbVJwUTZiY0Y5LTgyQ3JPVkhxMkhBc3huWGwyX3N6VUsxRWlubS1SbV9BNm1CZUh5ZjhOLTJWQTFjY1pHNTRoSV…
Alamar Biosciences, Inc. (ALMR) Revenue (Quarterly) - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE1wZHVUZGVjZVFSRHh3a2h5Zm1Ka0VnSmdFR1BIeFRrcnNaaFJ0MFBneXMwODNJRm1wZDJiVlB5WTJxQjVxbG5mS3ZMZkd2S2ZXeUV4QmlTckxpTzFtbjNvX3VkRGxOd1lEbW9ia0ZxMkdYakV2QzZ3?oc=5" target="_blank">Alamar …
Alamar Hits A High Note On Alzheimer’s Buzz - Trefis
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNd3NyVmlsVFhCb3g5Q0w0eXozMFpwWkRvU1JpTENnUkZmN0g2LTB2aVpWaWZKQmd6el9PUHJzMjU1WkNJUEcwWkFnVFdZZTE4Q291MnB1V2QwRjFydVJHcGVDcmkxSEh6QXpCQkNPMDB4R3g3bDAyWjhnY05XZ1JHRmYzZ0FFbzJKanpDM1…
Alamar Biosciences: Looking For An Early Detection - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxPNlB4dDNFRExXZTAzMENDYnpRVjdCUDR2aC1FdlJKY253TURKdlVZTWoycUc3aTQ0ZWoxNzFIWUpnVktwN0wzZlhBVUxTamJ3dGs0dUN5d3A0OUpjZ1VBY05ZQkhtYzhLVFd0RXJnTmdxWXFxbkp1LWNTS1dWUG96WmhCUUFLZ1h6SDBFVD…
ALMR — Frequently Asked Questions
What is the current share price of ALMR?
As of 2026-08-05 17:25 PDT, ALMR trades at $28.35 on NASDAQ/NYSE. Its 52-week range is $19.09 to $28.42.
What is the market capitalisation of ALMR?
ALMR has a market capitalisation of $1.89B on NASDAQ/NYSE.
What is the P/E ratio of ALMR?
ALMR trades at a trailing price-to-earnings (P/E) ratio of -63.24. Its price-to-book (P/B) ratio is -11.86.
What is the return on equity (ROE) of ALMR?
ALMR has a return on equity (ROE) of 18.76%. Its return on capital employed (ROCE) is -26.95%.
Is ALMR a good stock to buy?
This page provides a data-driven analysis of ALMR, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.